Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial

The reduction of low-density lipoprotein cholesterol (LDL-C) with evolocumab, a fully human monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9i), reduces the risk of major adverse cardiovascular events in patients with established atherosclerotic cardiovascular dis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2024-03, Vol.269, p.179-190
Hauptverfasser:	Bohula, Erin A., Marston, Nicholas A., Ruzza, Andrea, Murphy, Sabina A., De Ferrari, Gaetano M., Diaz, Rafael, Leiter, Lawrence A., Elliott-Davey, Mary, Wang, Huei, Bhatia, Ajay K., Giugliano, Robert P., Sabatine, Marc S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Apolipoprotein B Apolipoproteins Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Cerebral infarction Cholesterol Clinical trials Coronary artery disease Coronaviruses COVID-19 Density Diabetes Diabetes mellitus Drug dosages Health risks Heart attacks Heart diseases High density lipoprotein Ischemia Kexin Lipids Low density lipoprotein Monoclonal antibodies Myocardial infarction Participation Patients Placebos Population studies Proprotein convertases Risk Statins Stroke Subtilisin Vascular diseases Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!